Clinical Study Report (CSR) Synopses

Lilly provides the ability to search for Clinical Study Report (CSR) Synopses for Phase 2, Phase 3 and Phase 4 clinical trials that initiated on or after October 15, 2002, and studied the effects of medicines that are approved for use in the United States (U.S.) and the European Union (EU).

Lilly is working to complete the transfer of these CSR Synopses from different sources and will continue to update the search with historical trials. Newly completed studies will be provided in a timely manner for approved medicines after the approval of an indication has occurred in the U.S. and the EU and the primary peer-reviewed publication is available.

The information is not intended to replace the advice of your physician and is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Lilly products. If you have any questions regarding any information contained in this link, please consult with your physician.

Trade Name Generic Name
Adcirca®
Generic Name:
Tadalafil
Alimta®
Generic Name:
Pemetrexed
Cialis®
Generic Name:
Tadalafil
Cymbalta®
Generic Name:
Duloxetine
Cyramza®
Generic Name:
Ramucirumab
Effient®
Generic Name:
Prasugrel
Evista®
Generic Name:
Raloxifene
Forteo®
Generic Name:
Teriparatide
Gemzar®
Generic Name:
Gemcitabine
Glucagon™
Generic Name:
Glucagon for Injection
Humalog®
Generic Name:
Insulin Lispro Injection
Humatrope®
Generic Name:
Somatropin
Humulin®
Generic Name:
Human Insulin
Lartruvo™
Generic Name:
Olaratumab
Portrazza®
Generic Name:
Necitumumab
Prozac®
Generic Name:
Fluoxetine
Strattera®
Generic Name:
Atomoxetine
Symbyax®
Generic Name:
Olanzapine and Fluoxetine
Taltz®
Generic Name:
Ixekizumab
Trulicity®
Generic Name:
Dulaglutide
Verzenio®
Generic Name:
Abemaciclib
Yentreve®
Generic Name:
Duloxetine
Zyprexa®
Generic Name:
Olanzapine

Search CSR Synopses

Use this form to search the CSRs.